Dataset for the Development and Pilot Testing of the Expanded Prostate Index Composite – Filipino Version (EPIC-F)

This dataset was generated in the development and pilot testing of the Expanded Prostate Index Composite – Filipino Version (EPIC-F). The EPIC-32 was translated into Filipino using iterative forward and backward procedures with checks for semantic congruency. The translation was then evaluated by an expert panel consisting of a prostate cancer survivor and pertinent health professionals. The linguistically validated translation was evaluated to have cultural relevancy, adequacy, and representativeness by the expert panel, and to have good understandability and answerability by a representative pilot cohort of prostate cancer patients.THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV

Dataset for meta-analysis and metaregression of published outcomes data on definitive radiotherapy with or without chemotherapy for locally advanced cervical cancer in patients with contraindications to cisplatin

We performed a systematic review and meta-analysis to examine the outcomes of patients with locally advanced cervical cancer with contraindications to cisplatin, that were managed with definitive radiotherapy with or without chemotherapy or other co-interventions. We then performed a metaregression to examine the effects of clinical and treatment variables on outcomes.We identified eligible studies and extracted relevant data using a standardized data extraction template.Table 1 summarizes, per eligible study, the characteristics of the population or subgroup (including nature of contraindication to cisplatin), and the intervention groups (radiotherapy, brachytherapy and/or chemotherapy regimens).Table 2 summarizes our assessment of risk of bias for each study using templates that were based on the CASP Critical Appraisal Checklists.Table 3 and 4 summarize the outcomes (tumor response, survival, compliance rates, and toxicity) for each intervention group.Table 5 consolidates numerical data from Table 1, 3 and 4, suitable for meta-analyses and meta-regression.Table 6 is a composite database that contains the main template used in the preparation of the other datasets for the proprotional meta-analyses and meta-regression, given the variables and outcomes of interest.Table 7 is a composite database that contains the datasets used for the comparative meta-analyses.THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV

Dataset for meta-analysis and metaregression of published outcomes data on definitive radiotherapy with or without chemotherapy for locally advanced cervical cancer in patients with contraindications to cisplatin

We performed a systematic review and meta-analysis to examine the treatment outcomes in patients with locally advanced cervical cancer with contraindications to cisplatin, that were managed with definitive radiotherapy with or without chemotherapy. We then performed a metaregression to examine the effects of clinical and treatment variables on outcomes.We identified eligible studies and extracted relevant data using a standardized data extraction template.Table 1 summarizes the characteristics of the population or subgroup (including the nature of contraindication to cisplatin) and the intervention groups (radiotherapy, brachytherapy, and/or chemotherapy regimens) per each eligible study.Table 2 summarizes our assessment of the risk of bias for each study using templates that were based on the CASP Critical Appraisal Checklists.Tables 3 and 4 summarize the outcomes (tumor response, survival, compliance rates, and toxicity) for each intervention group.Table 5 consolidates numerical data from Tables 1, 3, and 4, suitable for meta-analyses and meta-regression.Table 6 is a composite database that contains the main template used in the preparation of the other datasets for the proportional meta-analyses and metaregression, given the variables and outcomes of interest.Table 7 is a composite database that contains the datasets used for the comparative meta-analyses.Figures 1 to 5b are Forests plots for pooled outcomes according to the intervention categories.Figures 6a to 6f are Forest plots for pooled outcomes according to the use or non-use of chemotherapy and nodal boost.THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV

Patient Decision Aid for Chemotherapy or Exclusion in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer: Development, Alpha Testing, and Peer Validation

PURPOSEIn locally advanced cervical cancer (LACC), adding cisplatin to radiotherapy (RT) improves survival but increases toxicity. Among patients with cisplatin contraindications, RT compliance may be compromised by toxicity because of cisplatin or a substitute. In shared decision making, a patient decision aid (PtDA) may decrease decisional conflict and attitudinal barriers, thereby improving treatment compliance.METHODSFollowing International Patient Decision Aid Standards (IPDAS) guidelines, a steering committee of two radiation oncologists, a gynecologic oncologist, an oncology nurse, a clinical psychologist, a cancer survivor, and a caregiver developed the chemotherapy or exclusion in cisplatin-intolerant patients with LACC (CECIL) prototype, a PtDA for cisplatin-intolerant patients with LACC deciding about adding chemotherapy to RT. The prototype was alpha-tested using the e-Delphi method. The patient decision aid research group Ottawa Acceptability Questionnaire was used to evaluate comprehensibility, length, amount of information, neutrality, and overall suitability for decision making. The prototype was then independently evaluated by local internal, local external, and international reviewers using the IPDAS checklist version 4, which encompasses information, probabilities, values, guidance, development, evidence, disclosure, plain language, and evaluation.RESULTSAlpha testing showed high practitioner acceptability (all items with mean and median scores ≥4; overall mean score 4.70 of 5.00) and good patient acceptability (all items rated good to excellent). Content validation showed that the PtDA satisfied all IPDAS six qualifying and six certification criteria, with high overall mean score (3.63 of 4.00) for all 17 applicable quality criteria.CONCLUSIONThe CECIL prototype shows good practitioner and patient acceptability, and content validity on peer review. Clinical testing to determine its effectiveness in reducing decisional conflict is ongoing

Quality of Life among Survivors of Locally Advanced Cervical Cancer Treated with Definitive Chemoradiotherapy in a Decade of Transition

Introduction The standard treatment for locally advanced cervical cancer (LACC) is concurrent chemoradiotherapy (CRT). External beam radiotherapy (EBRT) and brachytherapy (BRT) advances in the last decade have resulted in improved local control and survival. There is a lack of data on quality of life (QoL) among survivors. Objective This systematic review aimed to synthesize published data on QoL among LACC survivors treated with CRT and determine clinical factors of QoL. Methods Systematic literature search was conducted in PubMed, EBSCO, and ScienceDirect for relevant articles published in 2010 to 2020. Eligible studies on LACC survivors aged 18 years and above, who reported QoL after CRT, were included. Screening and data extraction were done by two pairs of independent reviewers. Results Five cohort studies, three cross sectional studies, and one clinical trial were included. Reported temporal evolution of QoL varied: two studies reported improvement of overall QoL, while four reported worsening of symptoms. Gastrointestinal, genitourinary, sexual, and psychosocial domains showed significant impairment. Age, stage, and baseline distress and physical condition were clinical determinants of body image, sexual activity, menopausal symptoms, distress, and dyspnea. Peripheral neuropathy, lymphedema, and dyspnea were reported, while grade 3 to 4 gastrointestinal, genitourinary, and musculoskeletal toxicities were rare. Conclusion Use of advanced EBRT and BRT techniques is associated with improving QoL in the first 3 years from treatment completion. Gastrointestinal, genitourinary, sexual, and psychosocial functions remain impaired on the long-term. Other late toxicities worth noting include peripheral neuropathy, lower limb edema, and insufficiency fractures

Shared Decision Making in Oncology and Its Implementation in Cervical Cancer Management in the Philippines: A Narrative Review

PURPOSEShared decision making (SDM) is an approach where clinicians and patients make decisions together using the best available evidence. Although much studied, recognized to be ethically imperative, and recommended in international health policies, it remains poorly implemented. In the Philippines, there are limited studies on patient decision making preferences and SDM. Practical guidance on the implementation of SDM or use of patient decision aids (PtDAs) is often not detailed in existing national clinical practice guidelines in oncology.METHODSWe performed a systematic search of Philippine literature on SDM in oncology and an iterative review of international literature on the philosophy and methods of SDM, the utility and effectiveness of PtDAs, and the facilitators and barriers to implementation or usage. We contextualized our review to the cervical cancer management and health service delivery in the Philippines.RESULTSLocal literature is limited to five scientific publications and two registered studies. International literature encompasses patient decisional preferences, the role of PtDAs and the standards for their development and evaluation, their effectiveness, and barriers and facilitators to their use in cancer-related decision making. We discussed the implications on the management of cervical cancer in the Philippines, challenges in health service delivery and standards, and SDM research.CONCLUSIONLocal SDM research is limited. Our preliminary experience in a multicenter clinical trial in Manila on PtDA use in the framework of SDM in cervical cancer suggest good patient and clinician acceptability. Challenges to implementation such as unfavorable financial situations, urgency of clinical decisions, low patient or caregiver educational attainment, and poor integration of multidisciplinary and SDM in organizational workflows will be important when implementing SDM in different settings